M/26/007 – Samsung Biologics/Human Genome
Transaction details
The proposed acquisition by Samsung Biologics America, Inc., a subsidiary of Samsung Biologics Co., Ltd. of sole control of Human Genome Sciences, a wholly owned subsidiary of GlaxoSmithKline Holdings (Americas) Inc., has been notified to the Competition and Consumer Protection Commission.
| Notification date | Decision date |
|---|---|
| Wednesday January 28, 2026 | |
| Parties Involved | Business activities |
|---|---|
| Samsung Biologics America, Inc. | Samsung Biologics America, Inc. is a subsidiary of Samsung Biologics Co., Ltd which is a company incorporated under the laws of the Republic of Korea and is engaged in biopharmaceutical manufacturing. Samsung Biologics Co., Ltd is a fully-integrated contract development and manufacturing organisation delivering end-to-end biologics to biotechnology and pharmaceutical companies. Samsung Biologics Co., Ltd is part of the Samsung conglomerate and it's shareholders include Samsung C&T Corporation and Samsung Electronics Co. Limited. Samsung is a conglomerate active in a wide array of industries, including electronics, shipbuilding, engineering and insurance. |
| Human Genome Sciences, Inc | Human Genome Sciences, Inc. is a indirectly wholly owned subsidiary of GSK pie (formerly GlaxoSmithKline). Human Genome Sciences, Inc. is a biopharmaceutical company that manufactures bulk drug substance products. Human Genome Sciences, Inc. operates two manufacturing plants in Maryland, the United States. |
| Economic sector | Media merger |
|---|---|
| Manufacturing | No |
| Submissions from third parties due by: | |
|---|---|
| Phase 1 | Phase 2 |
| Wednesday, February 11, 2026 | |
| Current status: Active |
|---|
| Simplified Merger Notification |
| Authorised Officer Assigned | Contact Details |
|---|---|
| Aodhán Frain | aodhanfrain@ccpc.ie |
Media enquiries: communications@ccpc.ie
